Look up one drug

Matched class: 24:04 Cardiac Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ATENOLOL, DIGOXIN, PROPAFENONE HCL Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE, VERAPAMIL HCL 24:00 CARDIOVASCULAR DRUGS

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:04 Cardiac Drugs

AMLODIPINE

· 56 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab

ACEBUTOLOL HCL

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab

AMIODARONE HCL

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

DIGOXIN

· 7 products · General benefit · strengths: 0.05mg/mL, 0.0625mg, 0.125mg · O/L, Tab

DILTIAZEM HCL

· 93 products · General benefit (91), Listed, not a benefit (2) · strengths: 120mg, 180mg, 240mg, 300mg, 360mg, 30mg, 60mg · ER Tab, LA Cap, SR Cap, Tab

DISOPYRAMIDE

· 3 products · Listed, not a benefit (1), General benefit (1), Temporary benefit (1) · strengths: 100mg · Cap

FLECAINIDE ACETATE

· 14 products · Listed, not a benefit (2), General benefit (12) · strengths: 50mg, 100mg · Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab

MEXILETINE HCL

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 100mg, 200mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:04 and 9 more

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

FELODIPINE

· 12 products · General benefit (10), Listed, not a benefit (2) · strengths: 2.5mg, 5mg, 10mg · ER Tab, SR Tab

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab

CILAZAPRIL & HYDROCHLOROTHIAZIDE

· 2 products · General benefit · strengths: 5mg/12.5mg · Tab

CLONIDINE HCL

· 17 products · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) · strengths: 0.025mg, 0.1mg, 0.2mg · Tab

DOXAZOSIN MESYLATE

· 12 products · Listed, not a benefit (3), General benefit (9) · strengths: 1mg, 2mg, 4mg · Tab

ENALAPRIL MALEATE

· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab

FOSINOPRIL SODIUM

· 12 products · Listed, not a benefit (2), General benefit (10) · strengths: 10mg, 20mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08 and 35 more

From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. VERAPAMIL HCL · Listed, not a benefit (2), General benefit (8), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), Off-Formulary Interchangeable, not an ODB benefit (3) • Angina resulting from coronary artery spasm. PM: https://pdf.hres.ca/dpd_pm/00082059.PDF; date JUN 30, 1989; DIN 00782483; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26

1 INDICATIONS NIFEDIPINE (nifedipine capsules) is indicated for: • Management of angina resulting from coronary artery spasm. • Management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. NIFEDIPINE may be used in combination with beta blocking drugs in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy care must be taken to monitor blood pressure closely, since severe hypotension can occur from the combined effects of the drugs (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular). 1.1 Pediatrics Pediatrics (< 18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 1.2 Geriatrics Geriatrics (≥ 65 years of age): Evidence from clinical studies and experience suggests that… https://pdf.hres.ca/dpd_pm/00073685.PDF PM date: JUN 16, 2010 Source product: NIFEDIPINE; DIN 00725110; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.